Global Wealth Management Investment Advisory Inc. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Global Wealth Management Investment Advisory Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 6.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,957 shares of the company’s stock after acquiring an additional 2,171 shares during the quarter. Johnson & Johnson makes up about 1.0% of Global Wealth Management Investment Advisory Inc.’s portfolio, making the stock its 27th biggest holding. Global Wealth Management Investment Advisory Inc.’s holdings in Johnson & Johnson were worth $4,911,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 27.1% during the fourth quarter. Opal Wealth Advisors LLC now owns 2,383 shares of the company’s stock worth $345,000 after buying an additional 508 shares in the last quarter. Wingate Wealth Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $233,000. Savant Capital LLC grew its holdings in shares of Johnson & Johnson by 0.3% during the fourth quarter. Savant Capital LLC now owns 248,256 shares of the company’s stock worth $35,903,000 after buying an additional 729 shares in the last quarter. Angeles Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 2.1% during the fourth quarter. Angeles Wealth Management LLC now owns 16,166 shares of the company’s stock worth $2,338,000 after buying an additional 329 shares in the last quarter. Finally, Tevis Investment Management grew its holdings in shares of Johnson & Johnson by 2.1% during the fourth quarter. Tevis Investment Management now owns 17,692 shares of the company’s stock worth $2,559,000 after buying an additional 358 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JNJ shares. Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.3 %

Shares of JNJ opened at $157.24 on Friday. The stock has a market capitalization of $378.58 billion, a PE ratio of 23.65, a P/E/G ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company’s 50-day simple moving average is $147.58 and its 200-day simple moving average is $156.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 earnings per share. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.15%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.